Companies are racing to expand the global biosimilar drugs market, Moody's Investors Service says in a new report, "Biosimilars: Parsing the Industry's Pipelines." And while biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, the world's largest pharmaceutical market. Biosimilar drugs are follow-on versions of complex biotechnology, or "biotech," drugs.